Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...

Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost ...

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...

The Ministry of the Interior of Taiwan presented the 2023 Table of Life on Saturday indicating that the average life expectancy in the country would increase b ...

Exploring innovative therapies and market trends in lupus nephritis treatment, highlighting advancements in patient care and emerging drug developments.

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...

B and T cells constitute the majority of infiltrating lymphocytes in the kidney and represent the local perpetrators of lupus nephritis (LN). Previous studies have found the enrichment of atypical B ...

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...